Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers

The trial was designed as a single-center, randomized, double-blind, single-dose parallel controlled phase I study to evaluate the similarity of pharmacokinetics and safety of Meperizumab injection and NUCALA® in healthy male volunteers.

The plan is to enroll 88 healthy subjects. After signing the written informed consent voluntarily, the subjects will undergo a series of examinations and information collection to determine whether they meet the inclusion criteria. The qualified subjects will be randomized and administered. Biological samples were collected and safety checked before and after administration according to protocol requirements. Adverse events occurred during the trial were collected, and the combination of drug use and non-drug treatment were asked and recorded in detail.

When the 90% confidence interval of geometric mean ratio of the main pharmacokinetic parameters of Meperizumab injection and NUCALA® was within the range of 80.00%-125.00%, it was proved that the pharmacokinetic characteristics of the two were similar.

Study Overview

• Status: Not yet recruiting
• Conditions: Granulomatosis With Polyangiitis; Hemophagocytic Syndrome
• Intervention / Treatment: Drug: Meperizumab injection; Drug: NUCALA®

• Study Type: Interventional
• Enrollment (Anticipated): 88
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Haimiao Yang, Master; Phone Number: 0431-86177635; Email: czfyyq728@163.com

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130021
      • Affiliated Hospital of Changchun University of Traditional Chinese Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• 1 Before the study, the informed consent was signed and the content, process and possible adverse reactions of the test were fully understood;
• 2 Able to complete the research according to the requirements of the test protocol;
• 3 Male subjects aged 18-55 (18 and 55 included);
• 4 Body weight ≥ 50 kg ≤90 kg, body mass index (BMI) ≥ 19 ≤ 26kg/m2;
• 5 Health status: No mental disorders, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolic abnormalities;
• 6 Subjects had no pregnancy plans and voluntarily used effective contraception for at least 6 months from 2 weeks prior to self-medication to their last use of study medication.

Exclusion Criteria:

• 1 Previous neuropsychiatric, respiratory, cardiovascular, digestive, hemolymph, hepatic and renal dysfunction, endocrine, skeletal and musculoskeletal disorders, or other diseases that the investigator judged might affect drug metabolism or safety;
• 2 Known allergy to meperizumab or its excipients;
• 3 Known history of allergic disease or allergy or history of asthma disease;
• 4 Prior treatment with meperizumab or an IL-5 receptor inhibitor, or other antibody or protein drugs that target the IL-5 receptor;
• 5 Who received any live viral vaccines within 2 months prior to infusion of the study drug, or who needed to be vaccinated between the screening period and the end of the study, who used the study drug within 12 months prior to administration of the study drug or planned to receive any monoclonal antibodies or biologic drugs within 12 months after administration of the study drug;
• 6 Patients who have unhealed wounds, ulcers or fractures, or who underwent major surgery within 3 months prior to infusion of the study drug, or who are expected to undergo major surgery within 2 months after study completion;
• 7 Any prescription, over-the-counter, vitamin product or herbal medicine used in the 2 weeks prior to taking the study drug;
• 8 Abnormal and clinically significant examinations during screening period;
• 9 Blood donation or significant blood loss within 3 months prior to taking the study drug (& GT; 450 ml);
• 10 Participated in any drug clinical trials within 3 months prior to taking the study drug;
• 11 Those who smoked more than 5 cigarettes a day 3 months before the experiment;
• 12 History of alcohol abuse (14 units of alcohol per week: 1 unit =360mL beer or 45mL 40% spirits or 150mL wine);
• 13 Those who are screened positive for drugs or have a history of drug abuse in the past five years or have used drugs in the three months prior to the test;
• 14 Screening positive for hepatitis (including hepatitis B and C), acquired immunodeficiency syndrome(AIDS) and syphilis;
• 15 The subject is unable to complete the test due to personal reasons;
• 16 Conditions that other researchers consider inappropriate for inclusion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Meperizumab injection; Subcutaneous injection of meperizumab once	Drug: Meperizumab injection; Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
Active Comparator: NUCALA®; Subcutaneous injection of NUCALA® once	Drug: NUCALA®; NUCALA® is a humanized monoclonal antibody of IgG1 injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak concentration(Cmax)	Peak maximum plasma drug concentration	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Area under drug concentration - time curve(AUC0-t)	Area under the curve from zero to the lowest detectable blood drug concentration	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The area under the curve extrapolating from zero to infinity(AUC0-∞)	Area under the curve from zero to infinity	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Peak concentration time(Tmax)	Time to reach maximum plasma concentration after dosing	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
half-life(T1/2)	The time it takes for serum drug concentrations to drop by half	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Elimination rate constant(λz)	The slope of the terminal segment of a semi-logarithmic curve	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Residual area percentage(AUC%Extrap)	The percentage of the difference between AUC0-∞ and AUC0-t as a percentage of AUC0-t	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Apparent clearance(CL/F)	Percentage of the body that eliminates organ-scavenging drugs	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Apparent volume of distribution(Vd/F)	Apparent volume of distribution after non-intravenous administration	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Physical examination	The doctor will percuss, look, and question the subject, and record any abnormalities in the skin, spine, or limbs	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Body temperature	Abnormal body temperature	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Pulse	Abnormal pulse	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Blood pressure	Abnormal blood pressure	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Electrocardiogram(ECG) QT Interval	Abnormal ECG QT Interval	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Anti-drug antibody(ADA)	ADA positive	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration
Neutralizing antibody(NAb)	NAb positive	0 hours before administration (within 60 minutes before administration) to 2016 hours after administration

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2022
• Primary Completion (Anticipated): October 1, 2022
• Study Completion (Anticipated): October 1, 2022

Study Registration Dates

• First Submitted: April 11, 2022
• First Submitted That Met QC Criteria: April 28, 2022
• First Posted (Actual): April 29, 2022

Study Record Updates

• Last Update Posted (Actual): April 29, 2022
• Last Update Submitted That Met QC Criteria: April 28, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Immune System Diseases; Lymphatic Diseases; Autoimmune Diseases; Lung Diseases; Vasculitis; Lung Diseases, Interstitial; Systemic Vasculitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Granulomatosis with Polyangiitis; Lymphohistiocytosis, Hemophagocytic
• Other Study ID Numbers: TQC3566-I-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No